Onabotulinum Toxin A in Direct Brow Lift
Direct Brow Lift, Scarring
About this trial
This is an interventional treatment trial for Direct Brow Lift focused on measuring onabotulinum toxin, direct brow lift, scarring, Botox
Eligibility Criteria
The patient population to be studied will include patients undergoing bilateral direct brow lifts at the Victoria General Hospital in Halifax, Nova Scotia.
Patients must meet all of the following inclusion criteria, and have none of the exclusion criteria listed below.
Inclusion criteria:
- Participants must be over 18 years of age
- Participants must be able to attend outpatient appointments at the Victoria General Hospital
- Participants must be able to give informed consent
Exclusion criteria:
- Known allergy to botulinum toxin
- Previous scarring in same region of surgical procedure
- Previous botulinum toxin injection within 6 months of surgical date for direct brow lift
- Currently pregnant or breast feeding
- History of keloid or hypertrophic scarring
- History of myasthenia gravis/ neuromotor disorder
Sites / Locations
- Eye Care Centre, Victoria General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
onabotulinum toxin A group (brow)
placebo group (brow)
Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration.
Product name: normal saline Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration.